Showing all 4 results
Darifenacin Prolonged Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix Prolonged-Release Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute physical stability of the controlled-release polymer.
Active Ingredient Strength Primary Clinical Function Darifenacin Hydrobromide USP/Ph.Eur.
(Equivalent to Darifenacin base)7.5 mg (PR) The Standard Titration & Geriatric Anchor: The definitive, highly efficacious starting and maintenance dose utilized for the vast majority of patients to control OAB symptoms with minimal side effects. Darifenacin Hydrobromide USP/Ph.Eur. 15 mg (PR) The Severe Refractory Macrodose: High-efficacy therapeutic payload utilized strictly for patients who require greater symptom relief and have demonstrated high tolerability to the 7.5 mg dose. Excipients Hypromellose (HPMC) / Dibasic Calcium Phosphate / Magnesium Stearate / Polyethylene Glycol / Titanium Dioxide / Premium Polymeric Film Hydrophilic PR Matrix / Diluent / Lubricant / Plasticizer / Opaque Film (Engineered specifically utilizing high-viscosity Hypromellose. Upon contact with gastrointestinal fluids, the tablet hydrates to form a thick, gelatinous outer layer that strictly controls the diffusion of the highly soluble hydrobromide salt over a 24-hour period) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urological dispensing regimens).
Mirabegron Extended-Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix ER Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute physical stability of the extended-release polymers.
Active Ingredient Strength Primary Clinical Function Mirabegron Ph.Eur./USP 25 mg (ER) Initiation / Renal Standard: Base therapeutic unit for assessing patient tolerance and for use in patients with severe renal or hepatic impairment. Mirabegron Ph.Eur./USP 50 mg (ER) Global Urology Standard: High-efficacy adult maintenance therapy for maximum suppression of urge urinary incontinence and detrusor overactivity. Excipients Polyethylene Oxide / Hypromellose (HPMC) / Butylated Hydroxytoluene (BHT) / Magnesium Stearate / Premium Opadry Film Swellable ER Polymer / Hydrophilic Matrix Base / Antioxidant / Lubricant (Engineered specifically to form an impenetrable, slow-eroding gel matrix in the GI tract, strictly metering the release of the active ingredient over 24 hours) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urology dispensing regimens).
Oxybutynin Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Polymeric Matrix Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE desiccant bottles to ensure the absolute chemical stability of the controlled-release hydrogel network.
Active Ingredient Strength Primary Clinical Function Oxybutynin Chloride USP/Ph.Eur. 5 mg (ER) Initiation Standard: Base once-daily titration unit for the gradual introduction of antimuscarinic therapy. Oxybutynin Chloride USP/Ph.Eur. 10 mg / 15 mg (ER) Global Clinical Standard: Advanced maintenance doses for severe, refractory Overactive Bladder and neurogenic detrusor overactivity. Excipients Hypromellose (HPMC) / Lactose Anhydrous / Macrogol (PEG) / Magnesium Stearate / Titanium Dioxide Hydrophilic Polymer Matrix / Diluent / Plasticizer / Premium Film-Coating (Engineered specifically to form a highly viscous external gel barrier upon swallowing, controlling the exact 24-hour drug diffusion rate) *Pack Sizes: Bottles of 30 or 10×10 Alu-Alu Blisters (Optimized specifically for strict, high-compliance 30-day chronic urology dispensing regimens).
Solifenacin Succinate Tablets
FreeA Solifenacin Succinate tablet is an antimuscarinic (anticholinergic) medication used to treat symptoms of an overactive bladder, such as frequent or urgent urination and urinary incontinence.
